Abstract
Mucopolysaccharidoses (MPS) are a group of lysosomal storage diseases that are resulted from abnormal accumulation of glycosaminoglycans. Among the progressive multi-organ abnormalities often associated with MPS diseases, the deterioration of central nervous system (CNS) is the most challenging manifestations to be tackled, due to the impermeability of the blood-brain-barrier (BBB). Evolved with recent development in stem cell biotechnology and gene therapy, several novel experimental approaches have been investigated in animal models. In this review, we will address different approaches attempting to bypass the BBB for neuropathic MPS treatment using cell- and gene-based therapies. Several neurological findings in CNS pathophysiology emerged with therapeutic investigation will also be discussed.
Keywords: Mucopolysaccharidoses, central nervous system, blood-brain-barrier, animal models, stem cells, gene therapy, abnormal accumulation of glycosaminoglycans, multi-organ abnormalities, deterioration of central nervous system, dysostosis multiplex, Hurler syndrome, enzyme trafficking, lysosomal enzyme release and reuptake, hematopoietic stem cell (HSC) transplantation
Current Pharmaceutical Biotechnology
Title: Cell-and Gene-based Therapeutic Approaches for Neurological Deficits in Mucopolysaccharidoses
Volume: 12 Issue: 6
Author(s): Dao Pan
Affiliation:
Keywords: Mucopolysaccharidoses, central nervous system, blood-brain-barrier, animal models, stem cells, gene therapy, abnormal accumulation of glycosaminoglycans, multi-organ abnormalities, deterioration of central nervous system, dysostosis multiplex, Hurler syndrome, enzyme trafficking, lysosomal enzyme release and reuptake, hematopoietic stem cell (HSC) transplantation
Abstract: Mucopolysaccharidoses (MPS) are a group of lysosomal storage diseases that are resulted from abnormal accumulation of glycosaminoglycans. Among the progressive multi-organ abnormalities often associated with MPS diseases, the deterioration of central nervous system (CNS) is the most challenging manifestations to be tackled, due to the impermeability of the blood-brain-barrier (BBB). Evolved with recent development in stem cell biotechnology and gene therapy, several novel experimental approaches have been investigated in animal models. In this review, we will address different approaches attempting to bypass the BBB for neuropathic MPS treatment using cell- and gene-based therapies. Several neurological findings in CNS pathophysiology emerged with therapeutic investigation will also be discussed.
Export Options
About this article
Cite this article as:
Pan Dao, Cell-and Gene-based Therapeutic Approaches for Neurological Deficits in Mucopolysaccharidoses, Current Pharmaceutical Biotechnology 2011; 12 (6) . https://dx.doi.org/10.2174/138920111795542679
DOI https://dx.doi.org/10.2174/138920111795542679 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
An Emerging Antiarrhythmic Target: Late Sodium Current
Current Pharmaceutical Design siRNA Delivery Using Nanocarriers – An Efficient Tool for Gene Silencing
Current Gene Therapy Insulin- and Growth Factor-Resistance Impairs Vascular Regeneration in Diabetes Mellitus
Current Vascular Pharmacology Biology of Heme in Health and Disease
Current Medicinal Chemistry Nanocarriers Assisted siRNA Gene Therapy for the Management of Cardiovascular Disorders
Current Pharmaceutical Design A synopsis on the linkage between age-related dementias and vascular disorders
CNS & Neurological Disorders - Drug Targets Metabolic Enzyme System and Transport Pathways in Chronic Kidney Diseases
Current Drug Metabolism Prevention of Cell Damage in Ischaemic-Reperfusion: Mitochondrial Respiratory Chain as a Pharmacological Target
Letters in Drug Design & Discovery Resistin: An Inflammatory Cytokine. Role in Cardiovascular Diseases, Diabetes and the Metabolic Syndrome
Current Pharmaceutical Design Brown Recluse Spider Venom: Proteomic Analysis and Proposal of a Putative Mechanism of Action
Protein & Peptide Letters Antioxidant Therapy in Critically Septic Patients
Current Drug Targets Drug-Induced Hypothermia in Stroke Models: Does it Always Protect?
CNS & Neurological Disorders - Drug Targets Inhalation Gases or Gaseous Mediators As Neuroprotectants for Cerebral Ischaemia
Current Drug Targets Copper and Heme-Mediated Abeta Toxicity: Redox Chemistry, Abeta Oxidations and Anti-ROS Compounds
Current Topics in Medicinal Chemistry The Important New Drug Target in Cardiovascular Medicine – the Vascular Glycocalyx
Cardiovascular & Hematological Disorders-Drug Targets Role of Platelet Function Testing in Clinical Practice: Current Concepts and Future Perspectives
Current Drug Targets Role of Sirtuins and Calorie Restriction in Neuroprotection: Implications in Alzheimers and Parkinsons Diseases
Current Pharmaceutical Design C60 Fullerene Derivatized Nanoparticles and their Application to Therapeutics
Recent Patents on Nanotechnology Recent Advances in Synthesis of PAR Ligands as Therapeutic Strategy for Inflammatory Diseases
Mini-Reviews in Medicinal Chemistry Therapeutic Modulation of Coagulation and Fibrinolysis in Acute Lung Injury and the Acute Respiratory Distress Syndrome
Current Pharmaceutical Biotechnology